OTC - ACTIVE INGREDIENT SECTION
glycerin
glycerin
triethanolamine, azelaic acid, portulaca oleracea ext, propolis ext, sodium hyaluronate, polyglutamic acid
skin protectant
keep out or reach of the children
apply appropriate to skin
- avoid direct sun exposure, keep it refrigerated or in cooler places
- avoid contact with eye
for exernal use only
| Class | Version | Type | Effective |
|---|---|---|---|
| GLYCERIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 6c6fc281-9445-2e9e-1c29-a09ddbc4299c | Product name | 2 | 20200213 |
| 2a856070-cbe7-4f85-be0f-09885ff91196 | Product name | 1 | 20150806 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 53010-5001-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e9bc-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 53010-5001-1 | JNH a-Clear Propolis Spot Serum | 30 mL in 1 BOTTLE | LIQUID | 30 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 53010-5001 | JNH A-CLEAR PROPOLIS SPOT SERUM (GLYCERIN) LIQUID [DAEDUCK LAB CO., LTD.] | 1 | Legacy NDC, 1 package rows | 20141016_ec6e2256-a9cb-4b5a-940e-fb2f4a340064.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| GLYCERIN | ACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| GLYCERIN | ACTIVE MOIETY | PDC6A3C0OX | 1 | |
| AZELAIC ACID | INACTIVE INGREDIENT | F2VW3D43YT | 1 | |
| HYALURONATE SODIUM | INACTIVE INGREDIENT | YSE9PPT4TH | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 53010-5001 | 53010-5001-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| GLYCERIN | PDC6A3C0OX | ACTIB |
| AZELAIC ACID | F2VW3D43YT | IACT |
| HYALURONATE SODIUM | YSE9PPT4TH | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | GEL / TOPICAL | 463 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRA-ARTICULAR | 23 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | LOTION / TOPICAL | 0.01 %w/w | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 053f57e6-b21d-471d-91c8-727b4dde0575 | ec6e2256-a9cb-4b5a-940e-fb2f4a340064 | 2014-10-15 | Warnings | 053f57e6-b21d-471d-91c8-727b4dde0575 ec6e2256-a9cb-4b5a-940e-fb2f4a340064 |
Adverse event summaries are temporarily unavailable. Other product information remains available.